semaglutide 503b pharmacy FDA moves to remove GLP-1 medications from Bulks List 503B Compounding Pharmacy | Clinical

Thanks to a mechanism that stimulates insulin and reduces glucagon secretions in a glucose-dependent manner, semaglutide has been shown to reduce fasting and postprandial blood glucose levels

If the medicine works, is tolerated, remains appropriate, and can be accessed, why build an elaborate science of stopping it

The interactions between GLP-1RAs and other drugs may affect drug efficacy or increase the risk of adverse reactions, as well as the dose adjustment of the combination of hypoglycemic drugs, which put forward higher requirements for clinicians

Typical Titration Schedule Practical Point: Dose increases are not instant